Circulate Health Secures $12 Million for Enhancing Longevity Research and Expanding TPE Clinics

Circulate Health Secures $12 Million for TPE Initiatives

Circulate Health, a pioneering startup in the field of longevity research, has successfully raised $12 million in seed funding to propel its research efforts and expand its network of therapeutic plasma exchange (TPE) treatment centers. This funding round was led by Khosla Ventures, with noteworthy contributions from Seaside Ventures and CSC Ventures.

Innovation in Aging Research

This investment comes on the heels of Circulate's recent trial study, recognized as the first of its kind to prove the effectiveness of TPE in enhancing healthspan and reducing biological age. TPE, which involves the separation and replacement of a patient's plasma, aims to tackle chronic diseases and inflammation, contributing to a longer, healthier life.

Dr. Brad Younggren, the CEO and co-founder of Circulate Health, stated, "The fact that Khosla has invested in our vision validates the potential of what we are undertaking." The startup has spent the past three years quietly conducting research into TPE’s numerous benefits for human health, all while collaborating with clinics to offer this innovative treatment.

Groundbreaking Clinical Trials

The scientific foundation of Circulate Health is backed by the groundbreaking research led by Dr. Eric Verdin, a distinguished geroscientist and the co-founder of Circulate. Recent findings, announced by the company, revealed that TPE, when combined with intravenous immunoglobulin (IVIG), resulted in an average reduction of 2.6 years in biological age among trial participants. This measurement was confirmed through advanced multi-omics biomarkers, showcasing the promising potential TPE holds for future medical practices.

"We have committed ourselves to high-quality medical care and thorough research to improve healthspan and address the complexities associated with aging," added Dr. Younggren.

Future Expansion Plans

With the newly acquired funding, Circulate Health aims to scale its operations significantly. Currently, the company collaborates with 24 partner clinics across eight states in the U.S., and it plans to increase this number to over 50 clinics by the close of 2025, both domestically and internationally. This expansion is set to provide greater access to individuals seeking therapies that can enhance their health markers and biological clocks efficiently.

Khosla Ventures’ Alex Morgan expressed enthusiasm for the direction of Circulate Health, stating, "We created Circulate to assess whether a well-known therapy like TPE could mitigate the negative effects of aging and introduce health benefits such as eliminating microplastics from the body. The preliminary clinical results look encouraging, and we are excited to support the team in making TPE more accessible to a wider audience."

A Collaborative Vision for Healthspan

The scientific advisory board of Circulate Health is complemented by experts such as Dr. Matt Kaeberlein and Dr. Alex Aravanis, further enhancing the company's strategic approach to longevity research. Their guidance is invaluable as Circulate Health continues to innovate and push the boundaries of what is possible in the domain of age-related treatments.

Those interested in learning more about Circulate Health and its groundbreaking work can visit www.circulate.health. The future looks promising as this company endeavors to redefine the landscape of aging through cutting-edge research and clinical applications.